Epirubicin/Cyclophosphamide Followed by Docetaxel as Primary Systemic Therapy in Breast Cancer

Annals of Cancer Research and Therapy - United States
doi 10.4993/acrt.22.19
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Japanese Society of Strategies for Cancer Research and Therapy

Related search

Neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide Chemotherapy Followed by Docetaxel in Refractory Patients With Locally Advanced Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
2007English

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

New England Journal of Medicine
Medicine
2006English

Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (Registration Number: ChiCTR1900023052)

Scientific Reports
Multidisciplinary
2019English

Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2016English

Primary Systemic Therapy of Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2006English

Primary Systemic Therapy for Operable Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1991English

Neoadjuvant Chemotherapy of Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy ( 'CEX' Therapy) for HER-2 Negative Breast Cancer, as Retrospective Study in Our Institute

Journal of Nippon Medical School
Medicine
2019English

A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients With Breast Cancer (CBCRT01)

International Journal of Cancer
Cancer ResearchOncology
2017English

P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer

Annals of Oncology
MedicineOncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy